Docoh
Loading...

VERV Verve Therapeutics

Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com.

VERV stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 Aug 21
18 Oct 21
31 Dec 21
Quarter (USD)
Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Cash on hand (at last report) 387.91M 387.91M
Cash burn (monthly) 5.65M (positive/no burn)
Cash used (since last report) 20.42M n/a
Cash remaining 367.49M n/a
Runway (months of cash) 65.0 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Jun 21 Casdin Private Growth Equity Fund Common Stock Conversion Acquire C No No 0 620,571 0 620,571
21 Jun 21 Casdin Private Growth Equity Fund Series B Preferred Stock Common Stock Conversion Dispose C No No 0 5,746,183 0 0
21 Jun 21 Casdin Partners Master Fund Common Stock Buy Acquire P No No 19 1,100,000 20.9M 2,417,596
21 Jun 21 Casdin Partners Master Fund Common Stock Conversion Acquire C No No 0 310,285 0 1,317,596
21 Jun 21 Casdin Partners Master Fund Common Stock Conversion Acquire C No No 0 1,007,311 0 1,007,311
21 Jun 21 Casdin Partners Master Fund Series B Preferred Stock Common Stock Conversion Dispose C No No 0 2,873,091 0 0
21 Jun 21 Casdin Partners Master Fund Series A-2 Preferred Stock Common Stock Conversion Dispose C No No 0 9,327,198 0 0
21 Jun 21 Wellington Biomedical Innovation Master Investors Common Stock Conversion Acquire C No No 0 1,152,490 0 2,495,571
21 Jun 21 Wellington Biomedical Innovation Master Investors Common Stock Conversion Acquire C No No 0 1,343,081 0 1,343,081
21 Jun 21 Wellington Biomedical Innovation Master Investors Series B Preferred Stock Common Stock Conversion Dispose C No No 0 10,671,482 0 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

60.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 69 0 NEW
Opened positions 69 0 NEW
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 1.67B 0 NEW
Total shares 29.2M 0 NEW
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Wellington Management 3.97M $232.08M NEW
FMR 3.45M $207.85M NEW
Casdin Capital 3.04M $183.05M NEW
Wellington Biomedical Innovation Master Investors 2.5M $79.66M NEW
Redmile 1.94M $116.68M NEW
Baker Bros. Advisors 1.42M $85.35M NEW
JHG Janus Henderson 1.41M $79.85M NEW
Rock Springs Capital Management 962.83K $58.01M NEW
JPM JPMorgan Chase & Co. 920.25K $55.45M NEW
Ra Capital Management 880.28K $53.04M NEW
Largest transactions
Shares Bought/sold Change
Wellington Management 3.97M +3.97M NEW
FMR 3.45M +3.45M NEW
Casdin Capital 3.04M +3.04M NEW
Wellington Biomedical Innovation Master Investors 2.5M +2.5M NEW
Redmile 1.94M +1.94M NEW
Baker Bros. Advisors 1.42M +1.42M NEW
JHG Janus Henderson 1.41M +1.41M NEW
Rock Springs Capital Management 962.83K +962.83K NEW
JPM JPMorgan Chase & Co. 920.25K +920.25K NEW
Ra Capital Management 880.28K +880.28K NEW

Financial report summary

?
Management Discussion
  • Research and development expenses were $13.4 million for the three months ended June 30, 2021, compared to $5.7 million for the three months ended June 30, 2020. The increase of approximately $7.8 million was primarily due to the following:
  • an increase in raw material costs and external expenses associated with developing and validating our manufacturing activities, including third-party CMOs, for use in our preclinical studies and future clinical trials of $3.0 million;
  • an increase in external expenses associated with preclinical studies (primarily animal-study costs) performed by outside consulting services, including third-party CROs, of $1.2 million;
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg

Proxies

No filings